Introduction
============

The mood stabilizer and anticonvulsant drug valproic acid and the antidepressants doxepin and venlafaxine are well-established psychotropic drugs that are used widely. Valproic acid is one of the most important antiepileptic agents ([@R27]; [@R2]) applicable in antiepileptic maintenance treatment as well as in epileptic emergency cases such as acute seizures or status epilepticus ([@R30]). Moreover, it is an established mood stabilizer used in the treatment of bipolar affective disorders ([@R9]; [@R6]), and additionally in nonpsychiatric indications such as vestibular migraine ([@R4]) or painful diabetic neuropathy ([@R7]).

The risk of a possible switch from depression to mania under treatment with antidepressants has led to a long debate on the use of these drugs in patients with bipolar disorder ([@R18]) in whom especially tricyclic antidepressants and venlafaxine could trigger a particular switch risk. Even if valproic acid monotherapy has been suggested to be efficacious ([@R5]) at least in Europe it is not unusual to treat severe depressive episodes in bipolar disorder with tricyclic antidepressants or venlafaxine ([@R1]), although not supported by evidence from randomized-controlled trials. In addition, many patients with epilepsy show depressive symptoms during the course of their illness ([@R20]), which, in some cases of severe depressive episodes, could be the reason for administration of a combination of a tricyclic antidepressant and valproic acid.

The occurrence of severe adverse events during combined treatment with valproic acid and antidepressant drugs has been described in case reports on a recurrence of absence seizures after starting comedication with low-dosed amitriptyline ([@R3]), and for status epilepticus after adding clomipramine to valproic acid ([@R8]). In experimental studies, a significant increase in the plasma concentration of amitriptyline and nortriptyline after the addition of valproic acid has been reported ([@R29]; [@R32]). An increase in nortriptyline serum levels in association with valproic acid comedication was also observed in two cases ([@R12]). Finally, we have previously published a drug--drug interaction study that showed a marked increase in amitriptyline and nortriptyline serum levels in combination with valproic acid ([@R28]).

Even though an influence of valproic acid on serum concentrations of tricyclic antidepressants such as amitriptyline, nortriptyline, and clomipramine has been reported repeatedly in the literature ([@R8]; [@R10]; [@R26]; [@R21]; [@R22]), to date, no studies have examined potential interactions between valproic acid and the tricyclic antidepressant doxepin or the dual selective antidepressant venlafaxine.

Materials and methods
=====================

As treatment with the antidepressants doxepin and venlafaxine as well as with the mood stabilizer valproic acid is routinely monitored by therapeutic drug monitoring (TDM) in the Department of Psychiatry, Psychosomatics and Psychotherapy of the University Hospital of Würzburg, we could retrospectively assess this TDM database for the time period January 2008 to December 2011 to identify all cases in which valproic acid in combination with doxepin or venlafaxine was administered. In cases of multiple serum-level determinations of the same drug, only the last determination was considered for evaluation to avoid multiple inclusion of the same individual. In a second step, we included a control group of patients receiving doxepin or venlafaxine without valproic acid comedication. This sample was matched with the patients in the valproic acid group with respect to sex, age, and dose of the respective antidepressant as well as number of comedications. The comedication was registered in detail on the request form. Patients with potential drug--drug interactions because of comedication with drugs that could induce or inhibit the metabolism of doxepin or venlafaxine according to a review of [@R15] were identified and excluded. We then compared the respective groups with or without valproic acid in terms of dose-corrected serum levels (ng/ml per applied mg of daily dose) of the antidepressants as well as the ratio of the metabolite/parent compound by the Mann--Whitney *U*-test. Spearman's *ρ* correlation coefficients were calculated to analyze the association between valproic acid and antidepressants' serum levels.

Serum levels were determined in the TDM laboratory of the Psychiatric University Hospital of Würzburg using an isocratic reversed-phase high-performance liquid chromatography method (doxepin, venlafaxine) and a spectrophotometric immunoassay (valproic acid), respectively. Internal and external (Cardiff Bioanalytical Services, The Cardiff Medic Center, Cardiff, UK) quality control programs were operated regularly without rejection.

Results
=======

From January 2008 to December 2011, 16 patients were identified in whom serum levels of doxepin and valproic acid were determined and 41 patients in whom serum levels of venlafaxine and valproic acid were measured. From the same time period, a sample of control patients receiving doxepin and venlafaxine without valproic acid was obtained and matched for sex, age, and dose of the antidepressant agent ([Table 1](#T1){ref-type="table"}).

###### 

Comparison of the sample with combined doxepin or venlafaxine and valproic acid treatment and the matched control samples of antidepressants without valproic acid in terms of matching variables and serum levels of antidepressants (Mann--Whitney *U*-test)

![](yic-29-206-g001)

Patients receiving valproic acid and doxepin had higher mean dose-corrected serum levels of doxepin, *N*-doxepin, and doxepin+*N*-doxepin in comparison with patients treated with the antidepressant alone. Whereas four of 16 patients in the doxepin plus valproic acid sample showed a total serum level of doxepin+*N*-doxepin above the alert level of 300 ng/ml ([@R15]), in the control group, this was not the case in any of the 16 patients (*χ*^2^ *P*\<0.05). In patients receiving venlafaxine and valproic acid, the mean serum concentration of *O*-desmethylvenlafaxine was higher than that in patients treated with venlafaxine alone. For dose-corrected serum levels of venlafaxine+*O*-desmethylvenlafaxine, there only was a trend for a difference (0.05\<*P*\<0.10, [Table 1](#T1){ref-type="table"}) whereas the parent compound showed no difference. In the total serum concentration of venlafaxine+*O*-desmethylvenlafaxine, two of 41 patients in the valproic acid comedication sample exceeded the alert level (800 ng/ml; [@R15]) whereas none in the group receiving venlafaxine without valproic acid exceeded this level. However, this difference was not statistically significant.

The serum concentrations of the respective antidepressant and its metabolite in relation to the daily dose of the antidepressants in patients with and without valproic acid comedication are shown in [Figs 1 and 2](#F1 F2){ref-type="fig"}. The ratio of the metabolite to parent compound did not differ between patients with or without valproic acid for both drugs ([Table 1](#T1){ref-type="table"}).
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On examining a potential association between the serum level of valproic acid and the dose-corrected serum levels of the respective antidepressants and their metabolites, a significant correlation (Spearman's *ρ*) was found between valproic acid and doxepin+*N*-doxepin serum levels ([Fig. 3](#F3){ref-type="fig"}). In terms of dose-corrected serum levels of venlafaxine+*O*-desmethylvenlafaxine (*r*=0.191, *P*=0.231, *n*=41), there was no significant correlation with the valproic acid serum concentration.

![Scatterplot of dose-corrected serum level of doxepin (DOX)+*N*-DOX \[(ng/ml)/(mg/day)\] and serum level of valproic acid (VPA) (Spearman's *ρ r*=0.602, *P*\<0.014, *n*=16).](yic-29-206-g004){#F3}

Discussion
==========

Our results indicate a clinically relevant increase in the serum concentrations of doxepin and *O*-desmethylvenlafaxine if a comedication with valproic acid is administered. In patients receiving doxepin and valproic acid, there was also a significant positive correlation between the serum levels of valproic acid and dose-corrected serum level of the antidepressant.

An obvious limitation is the retrospective nature of the study, which, in principle, cannot determine any causal relationship. Thus, the results of this study are of an explorative nature and have to be confirmed by prospective investigations. Furthermore, our study did not take into account the fact that both doxepin and venlafaxine are formulated as a mixture of *trans-*stereoisomers and *cis*-stereoisomers ([@R13]). Even if a potential pharmacokinetic influence of psychiatric and somatic comedication was controlled for by excluding patients who received a comedication with drugs known for their inducing or inhibiting properties in terms of the metabolic activity of cytochrome P450 enzymes, the possibility of an undetected drug--drug interaction cannot be ruled out completely. Therefore, the polypharmacy that was observed in all the patients studied in both naturalistic samples might have compromised the analysis. In terms of the number of simultaneously administered psychotropic drugs, there was no significant difference between patients with and without valproic acid for any of the antidepressant drugs evaluated. Moreover, both groups did not differ with respect to sex, age, or dose of the antidepressant agent.

In terms of valproic acid and clomipramine, [@R8] reported the case of a patient with status epilepticus associated with a combination of valproic acid and clomipramine. They found elevated serum levels of clomipramine despite applying a relatively small dose (75 mg), which was also observed by [@R10]. In a patient who received a comedication with valproic acid, elevated serum levels of amitriptyline and nortriptyline resulting in a severe cardiac adverse effect (Brugada syndrome) were described by [@R24]. However, the authors did not discuss a possible causal role of an interaction between amitriptyline and valproic acid, which shows the importance of a further clarification of the interaction potential of a combination of valproic acid and tricyclic antidepressants. In contrast, an increase in the serum level of another tricyclic antidepressant, desipramine, after discontinuation of valproic acid has been described ([@R16]), suggesting that potential interactions between valproic acid and antidepressants could result in different effects on serum levels of the antidepressants.

According to the results of the present study, there is not only a significant influence of valproic acid on the serum level of doxepin but also a significant correlation between dose-corrected serum level of doxepin+*N*-doxepin and valproic acid serum level. As a significant influence of amitriptyline on the plasma half-life of valproic acid has been described ([@R23]) according to our results, a change in valproic acid metabolism by doxepin might also be assumed.

However, the mechanism of the influence of valproic acid on doxepin and venlafaxine metabolism still remains unclear. Both doxepin and venlafaxine are metabolized mainly by CYP2D6 and CYP2C19. To a minor degree, doxepin is metabolized by CYP2C9 and venlafaxine by CYP3A4 ([@R15]). According to [@R31] valproic acid *in vitro* inhibited CYP2C19 as well as CYP3A4 slightly, and CYP2C9 to a larger extent. The latter might be the main reason for the considerable increase in doxepin+*N*-doxepin in combination with valproic acid. Therefore, the addition of valproic acid in patients treated with substrates of CYP2C9 might be problematic as a considerable increase in the serum level of the respective drug might occur, even if alternative metabolic pathways exist. Whereas CYP2C19 contributes considerably toward *N*-demethylation of doxepin, CYP2C9 seems to play only a minor role in the metabolism of doxepin ([@R14]). Nevertheless, an inhibition of its metabolic activity of CYP2C9 might be followed by an increase in doxepin serum concentrations ([@R17]). In addition to an influence of valproic acid by inhibition of CYP2C9, the influence of saturated pathways must be considered as valproic acid is also metabolized by CYP2C9.

Similar to the study of [@R29] on unchanged ratios of nortriptyline and amitriptyline before and after the addition of valproic acid, the present study showed no differences in the ratios of the metabolite and the parent compound for doxepin in patients with and without valproic acid comedication. As, according to [@R17], the doxepin as well as the *N*-doxepin serum level might be elevated by an inhibition of CYP2C9, our result of a lack of influence on the ratio *N*-doxepin/doxepin is in agreement with these findings. In contrast to the strong inhibitory influence of valproic acid on the metabolism of doxepin, in the venlafaxine sample, only a significant increase in the metabolite *O*-desmethylvenlafaxine, which is also known as desvenlafaxine, was found. Even if CYP2D6 is dominant, in addition to CYP2C19, CYP2C9 also plays a role in the *N*-demethylation of venlafaxine. However, inhibitors of CYP2C9 showed no consistent inhibition of *O*-desmethylvenlafaxine formation ([@R11]). However, CYP2C9, in addition to CYP2C19 and CYP3A, contributes considerably toward the formation of *N*-desmethylvenlafaxine ([@R11]). Even if some authors disregard an influence of CYP2C9 on the *N*-demethylation of venlafaxine ([@R25]; [@R19]), the results of the present study suggest a significant contribution of CYP2C9 because of the higher *O*-desmethylvenlafaxine serum levels in the valproic acid comedication sample. In particular, the inhibition of valproic acid on the *N*-demethylation pathway might lead to a stronger *O*-demethylation and as a consequence to higher serum levels of *O*-desmethylvenlafaxine. On the basis of this interpretation, it must be assumed that a treatment with desvenlafaxine that is chemically identical to venlafaxine's major metabolite *O*-desmethylvenlafaxine and marketed as an original drug is not influenced by valproic acid comedication.

In contrast to previous findings ([@R28]) showing a significant difference in the ratios of nortriptyline/amitriptyline in the samples with and without valproic acid comedication as an indicator of a change in metabolism by valproic acid, the present study found no differences in the ratios of the metabolite and the parent compound for doxepin and venlafaxine in patients with and without valproic acid comedication. Therefore, the first step of biotransformation of doxepin and venlafaxine does not seem to be influenced significantly by valproic acid, but possibly further steps in the metabolic pathways.

According to the results of this naturalistic study, there is a significant influence of valproic acid comedication on the dose-corrected doxepin+*N*-doxepin serum concentration (mean elevation of 124%) and on the dose-corrected *O*-desmethylvenlafaxine serum concentration (mean elevation of 27%), but only a trend of an influence on the dose-corrected venlafaxine+*O*-desmethylvenlafaxine serum concentration (mean elevation 17%). Adverse events were not documented systematically in this study, but case reports in the literature suggest that especially in treatment with tricyclic antidepressants, severe adverse effects can be induced by a considerable increase in serum levels ([@R3]; [@R8]; [@R28]). The significant positive correlation between valproic acid serum level and dose-corrected doxepin+*N*-doxepin serum level indicates that in addition to a careful dosage of doxepin lower valproic acid doses are also advisable. To the best of our knowledge, no report of a significant correlation between the serum levels of an antidepressant and a mood stabilizer has been published thus far; yet, clinicians should be aware of such an interaction. As a consequence, a combination treatment of valproic acid and tricyclic antidepressant drugs such as amitriptyline, nortriptyline, doxepin, or clomipramine should be avoided and other antidepressant drugs with a better safety profile and less interaction potential should be preferred. A comedication of valproic acid and venlafaxine should also be administered with caution. If valproic acid is applied in combination with these antidepressants, for reasons of safety, they should be used with great caution, avoiding high doses completely and administering half of the usual dose. Dose adjustment by TDM will be very helpful and should be used regularly if available.
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